AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12237988 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 41
Study 12237988 — intervention group
Group type: COMPARATOR
Intervention: Nurse interaction (Control)
Number of subjects: 41
Study 9809892 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 4312
Study 9809892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4312
Study 8592249 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril hydrochloride (5 mg once a day, increased to 10 mg if necessary)
Number of subjects: 231
Study 8592249 — intervention group
Group type: COMPARATOR
Intervention: Enalapril maleate (5 mg once a day, increased to 10 mg if necessary)
Number of subjects: 231
Study 8592249 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril hydrochloride
Number of subjects: 231
Study 8592249 — intervention group
Group type: COMPARATOR
Intervention: Enalapril maleate
Number of subjects: 231
Study 2650524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 1000
Study 608009 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative procedure (mammary resection plus axillary dissection plus radiotherapy)
Number of subjects: 331
Study 608009 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 331
Study 31239119 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (15 weeks, 3 times per week, 8 exercises, 8-12 repetitions, individualized loads)
Number of subjects: 65
Study 31239119 — intervention group
Group type: COMPARATOR
Intervention: Unchanged physical activity (control group)
Number of subjects: 65
Study 28320991 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model for contrast-induced nephropathy (CIN) based on age > 75 years, creatinine clearance (CrCl) < 60 mL/minute, and congestive heart failure (CHF)
Number of subjects: 1286
Study 28320991 — intervention group
Group type: COMPARATOR
Intervention: CIN group
Number of subjects: 1286
Study 26082614 — intervention group
Group type: EXPERIMENTAL
Intervention: LMV + ADV
Number of subjects: 252
Study 26082614 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT + ADV
Number of subjects: 252
Study 26082614 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV + ADV
Number of subjects: 252
Study 26082614 — intervention group
Group type: COMPARATOR
Intervention: LMV + ADV, LdT + ADV, ETV + ADV
Number of subjects: 252
Study 23421487 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure at 100 μg/m³ PM₁₀ for 2 hours
Number of subjects: 14
Study 23421487 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure for 2 hours
Number of subjects: 14
Study 22384543 — intervention group
Group type: EXPERIMENTAL
Intervention: SNMRM + TAI
Number of subjects: 62
Study 22384543 — intervention group
Group type: COMPARATOR
Intervention: TAI
Number of subjects: 62
Study 19332035 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pharmacological agents including antidepressants, anti-adrenergic agents, anticonvulsants, benzodiazepines, atypical antipsychotics, and novel agents
Number of subjects: 0
Study 16452647 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 238
Study 15356820 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir-indinavir
Number of subjects: 0
Study 15356820 — intervention group
Group type: COMPARATOR
Intervention: indinavir
Number of subjects: 0
Study 15356820 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-indinavir
Number of subjects: 0
Study 11696664 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 17
Study 11696664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9456189 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 130 mg/m2 every 3 weeks until disease progression or cumulative dose of 1000 mg/m2 or heart failure occurred
Number of subjects: 67
Study 9456189 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin treatment
Number of subjects: 67
Study 9456189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined criteria: age >=50 years, baseline LVEF <=0.60, decrease in LVEF to 0.50
Number of subjects: 67
Study 7856686 — intervention group
Group type: EXPERIMENTAL
Intervention: One subdermal estradiol implant
Number of subjects: 36
Study 7856686 — intervention group
Group type: EXPERIMENTAL
Intervention: Three subdermal estradiol implants
Number of subjects: 36
Study 7856686 — intervention group
Group type: COMPARATOR
Intervention: Both groups (one and three implants)
Number of subjects: 36
Study 2159054 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vindesine (V) 3 mg/m2 every 2 weeks
Number of subjects: 435
Study 2159054 — intervention group
Group type: EXPERIMENTAL
Intervention: V 3 mg/m2 weekly for 5 weeks plus mitomycin (VM) 20 mg/m2 day 1 and then 15 mg/m2 every 6 weeks
Number of subjects: 435
Study 2159054 — intervention group
Group type: EXPERIMENTAL
Intervention: V at the more intensive dose rate plus cisplatin (VC) 120 mg/m2 with forced diuresis on days 1 and 29 and then every 6 weeks
Number of subjects: 435
Study 7419959 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK (0.066, 0.125, 0.25, and 0.5 CHR U/kg/hr)
Number of subjects: 6
Study 7419959 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-OP (40 ng/kg/hr) plus secretin (0.25 U/kg/hr)
Number of subjects: 6
Study 7419959 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-OP (20, 40, 80, and 160 ng/kg/hr)
Number of subjects: 6
Study 31095724 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 450
Study 31095724 — intervention group
Group type: COMPARATOR
Intervention: Direct radiofrequency ablation (dRFA)
Number of subjects: 450
Study 31095724 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect radiofrequency ablation (iRFA)
Number of subjects: 450
Study 31095724 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (EVLA, dRFA, iRFA)
Number of subjects: 450
Study 28131050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer-cycling with strict coach-supervision (STRICT, N=3; n=35)
Number of subjects: 95
Study 28131050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer-cycling with autonomy-supportive minimal contact coach-supervision (AUT, N=3; n=36)
Number of subjects: 95
Study 28131050 — intervention group
Group type: COMPARATOR
Intervention: Both ergometer-cycling programs (STRICT and AUT)
Number of subjects: 95
Study 28131050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-adherers (adherence≥80%)
Number of subjects: 95
Study 28131050 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON, N=2; n=24)
Number of subjects: 95
Study 25264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine IR (100 mg)
Number of subjects: 36
Study 25264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine MR (400 mg once daily for 8 days)
Number of subjects: 36
Study 25264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine IR
Number of subjects: 36
Study 25264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine MR
Number of subjects: 36
Study 25264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 36
Study 24252510 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a weight management service with follow-up
Number of subjects: 1824
Study 24252510 — intervention group
Group type: COMPARATOR
Intervention: Advice to lose weight on medical grounds
Number of subjects: 1824
Study 21353585 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-blood cardioplegia supplemented with 16 mmol l⁻¹ Mg²⁺
Number of subjects: 691
Study 21353585 — intervention group
Group type: COMPARATOR
Intervention: Warm-blood cardioplegia supplemented with 5 mmol l⁻¹ Mg²⁺
Number of subjects: 691
Study 19596563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol provocation system (APS) using a single concentration of 16mg/mL methacholine (APS-SC)
Number of subjects: 52
Study 19596563 — intervention group
Group type: COMPARATOR
Intervention: Standard dosimeter method (SDM)
Number of subjects: 52
Study 18035733 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulating rate ABR in MV
Number of subjects: 124
Study 18035733 — intervention group
Group type: COMPARATOR
Intervention: High stimulating rate ABR in PCIV
Number of subjects: 124
Study 18035733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral MRI in MV
Number of subjects: 124
Study 18035733 — intervention group
Group type: COMPARATOR
Intervention: Cerebral MRI in PCIV
Number of subjects: 124
Study 18035733 — intervention group
Group type: COMPARATOR
Intervention: Abnormal blood pressure in PCIV
Number of subjects: 124
Study 18035733 — intervention group
Group type: COMPARATOR
Intervention: Abnormal blood fat/pathoglycemia in PCIV
Number of subjects: 124
Study 18035733 — intervention group
Group type: COMPARATOR
Intervention: Abnormal cervical vascular ultrasound in PCIV
Number of subjects: 124
Study 18035733 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion sickness in MV
Number of subjects: 124
Study 18035733 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion sensitivity in MV
Number of subjects: 124
Study 18035733 — intervention group
Group type: EXPERIMENTAL
Intervention: Photophobia/phonophobia in MV
Number of subjects: 124
Study 18035733 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ocular motion function in MV
Number of subjects: 124
Study 15271108 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider experience taking care of large numbers of elderly patients
Number of subjects: 800
Study 15271108 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider having a certificate of added qualifications in geriatrics
Number of subjects: 800
Study 15271108 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice style embodying traditional geriatric principles of care (prescribing no high-risk medications)
Number of subjects: 800
Study 15271108 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice style embodying traditional geriatric principles of care (managing geriatric syndromes)
Number of subjects: 800
Study 15271108 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice style embodying traditional geriatric principles of care (team care approach)
Number of subjects: 800
Study 11405513 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg b.i.d. for 10-14 days
Number of subjects: 10
Study 11405513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11405513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 200 mg intravenously prior to salbutamol
Number of subjects: 10
Study 8656156 — intervention group
Group type: EXPERIMENTAL
Intervention: Health decisions
Number of subjects: 3
Study 8656156 — intervention group
Group type: EXPERIMENTAL
Intervention: Money decisions
Number of subjects: 3
Study 1295808 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) co-treatment
Number of subjects: 0
Study 1295808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6707409 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician/geriatric nurse practitioner/social worker home care team
Number of subjects: 33
Study 6707409 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing and other home care services (Control)
Number of subjects: 33
Study 31597083 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 (10 mg)
Number of subjects: 32
Study 31597083 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 (50 mg)
Number of subjects: 32
Study 31597083 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 (200 mg)
Number of subjects: 32
Study 31597083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31597083 — intervention group
Group type: EXPERIMENTAL
Intervention: XC8 (all doses)
Number of subjects: 32
Study 30293349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) for MMAF patients
Number of subjects: 15
Study 30293349 — intervention group
Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI) for OA patients
Number of subjects: 15
Study 24480721 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised invitation letter
Number of subjects: 13551
Study 24480721 — intervention group
Group type: COMPARATOR
Intervention: Original invitation letter
Number of subjects: 13551
Study 22093076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately rough implants (TiUnite)
Number of subjects: 18
Study 22093076 — intervention group
Group type: COMPARATOR
Intervention: Minimally rough implants (turned)
Number of subjects: 18
Study 22093076 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially edentulous patients
Number of subjects: 18
Study 22093076 — intervention group
Group type: COMPARATOR
Intervention: Fully edentulous patients
Number of subjects: 18
Study 21048171 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar fascia-specific stretching (Group I, n = 54)
Number of subjects: 102
Study 21048171 — intervention group
Group type: COMPARATOR
Intervention: Radial shock-wave therapy (Group II, n = 48)
Number of subjects: 102
Study 17514344 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of naltrexone
Number of subjects: 146
Study 17514344 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of naltrexone
Number of subjects: 146
Study 17514344 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of naltrexone followed by 12 weeks of placebo
Number of subjects: 146
Study 15720582 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction-instructed group
Number of subjects: 0
Study 15720582 — intervention group
Group type: COMPARATOR
Intervention: Noninstructed group
Number of subjects: 0
Study 12142185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Beriplast P)
Number of subjects: 52
Study 12142185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 10445774 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 65
Study 10445774 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 65
Study 7768380 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (300 micrograms three times a day)
Number of subjects: 129
Study 7768380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 7768380 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 129
Study 1645641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 1645641 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (Control)
Number of subjects: 0
Study 7326866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate at 2 of 3 mg/day for 9 or 13 weeks
Number of subjects: 14
Study 31185971 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-feedback
Number of subjects: 94
Study 31185971 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-feedback
Number of subjects: 94
Study 31185971 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 29068862 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol blend (PPB)
Number of subjects: 40
Study 29068862 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 40
Study 29068862 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 25648223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (Training group)
Number of subjects: 60
Study 25648223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pelvic floor muscle exercise)
Number of subjects: 60
Study 24969283 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of rifaximin twice a day for 12 weeks
Number of subjects: 168
Study 24969283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 24969283 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of rifaximin
Number of subjects: 168
Study 22000821 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder (n=342)
Number of subjects: 679
Study 22000821 — intervention group
Group type: COMPARATOR
Intervention: No reminder (n=337)
Number of subjects: 679
Study 22000821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 679
Study 19297236 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses offered before spectacle dispensing (test group)
Number of subjects: 91
Study 19297236 — intervention group
Group type: COMPARATOR
Intervention: No contact lenses offered (control group)
Number of subjects: 91
Study 17502725 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PAIG injections (weeks 0 and 6)
Number of subjects: 31
Study 17502725 — intervention group
Group type: COMPARATOR
Intervention: Delayed PAIG injections (weeks 12 and 18)
Number of subjects: 31
Study 17502725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both immediate and delayed PAIG injections
Number of subjects: 31
Study 15039688 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated Pediatric Risk of Admission (PRISA) score
Number of subjects: 0
Study 15039688 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated PRISA score
Number of subjects: 0
Study 11795993 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Number of subjects: 156
Study 11795993 — intervention group
Group type: COMPARATOR
Intervention: Neutrally wedged insoles (Control)
Number of subjects: 156
Study 9932756 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation using propofol (10 mg/ml) and alfentanil (25 microg/ml)
Number of subjects: 66
Study 9932756 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazemuls (10-20 mg) and pethidine (50 mg)
Number of subjects: 66
Study 7804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium concentration in children with cancer
Number of subjects: 205
Study 7804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione peroxidase activity in children with cancer
Number of subjects: 205
Study 7804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium concentration in 3-7 year-old children with cancer
Number of subjects: 205
Study 7804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione peroxidase activity in 3-7 year-old children with cancer
Number of subjects: 205
Study 7804031 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium concentration and glutathione peroxidase activity before and during treatment with cytostatics
Number of subjects: 205
Study 3369334 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 42
Study 3369334 — intervention group
Group type: COMPARATOR
Intervention: Smoking habit change information
Number of subjects: 42
Study 3369334 — intervention group
Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 42
Study 31999315 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and Coping (LC) in cardiac rehabilitation
Number of subjects: 825
Study 31999315 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (CR)
Number of subjects: 825
Study 31981129 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted Persian version of the Brace Questionnaire (P-BrQ)
Number of subjects: 51
Study 28593360 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-delivered intervention (12-session cognitive behavioural informed handbook with telephone-based coaching support)
Number of subjects: 62
Study 28593360 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-delivered intervention
Number of subjects: 62
Study 28593360 — intervention group
Group type: COMPARATOR
Intervention: Standard community care (control)
Number of subjects: 62
Study 26141665 — intervention group
Group type: EXPERIMENTAL
Intervention: In-pain group (n=18)
Number of subjects: 40
Study 26141665 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 40
Study 22584554 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.1% sodium bicarbonate
Number of subjects: 18
Study 22584554 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.05% sodium bicarbonate
Number of subjects: 18
Study 22584554 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 18
Study 19796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Open pro‐peritoneal repair
Number of subjects: 100
Study 19796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein tension‐free mesh repair
Number of subjects: 100
Study 19796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal pro‐peritoneal (TAPP) repair
Number of subjects: 100
Study 19796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal (TEP) hernia repair
Number of subjects: 100
Study 19796714 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic operations (TEP and TAPP)
Number of subjects: 100
Study 19796714 — intervention group
Group type: COMPARATOR
Intervention: Open repairs (control group)
Number of subjects: 100
Study 17352869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruyiping
Number of subjects: 80
Study 17352869 — intervention group
Group type: COMPARATOR
Intervention: Runing II
Number of subjects: 80
Study 15871132 — intervention group
Group type: EXPERIMENTAL
Intervention: CX3CR1 I/I249 genotype
Number of subjects: 1055
Study 15871132 — intervention group
Group type: COMPARATOR
Intervention: V249-T280 haplotype
Number of subjects: 1055
Study 12116042 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination during the first year of life
Number of subjects: 0
Study 12116042 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Number of subjects: 0
Study 10455474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry at 50% of VO2 Peak
Number of subjects: 10
Study 10455474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry at 75% of VO2 Peak
Number of subjects: 10
Study 7887717 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cannula (1.5 cm)
Number of subjects: 18
Study 7887717 — intervention group
Group type: COMPARATOR
Intervention: Long cannula (7.0 cm)
Number of subjects: 18
Study 2231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) hydralazine thrice daily, daily doses of 75, 150, or 300 mg
Number of subjects: 181
Study 2231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) hydralazine twice daily, daily doses of 75, 150, or 300 mg
Number of subjects: 181